Key Insights

Highlights

Treatment Research

2 treatments under study, led by Ruxolitinib

Research Leaders

6 sponsors active, led by National Marrow Donor Program

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

66.7%

2 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

3Total
Phase 3 (2)
Phase 4 (1)

Trial Status

Terminated2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06462469Phase 4Active Not RecruitingPrimary

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT04934670Phase 3TerminatedPrimary

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

NCT04128319Phase 3TerminatedPrimary

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

Showing all 3 trials

Research Network

Common Treatments

  • Ruxolitinib2
  • Tguard2

Active Sponsors

  • National Marrow Donor Program2
  • National Cancer Institute (NCI)2
  • Xenikos2
  • Blood and Marrow Transplant Clinical Trials Network2
  • National Heart, Lung, and Blood Institute (NHLBI)2

Top Investigators

Activity Timeline